Adult lymphoblastic lymphoma:: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials
Adult lymphoblastic lymphoma:: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials
复制标题
DOI：
10.1038/sj.leu.2403095
复制
发表时间：
2003-11-01
期刊：
影响因子：
11.4
通讯作者：
Brice, P
中科院分区：
文献类型：
--
作者：
Le Gouill, S;Lepretre, S;Brice, P
自1987年以来，GELA已开始对侵袭性非霍奇金淋巴瘤（NHL）进行多中心前瞻性试验。直到1997年，淋巴母细胞性淋巴瘤（LBL）被纳入这些研究，92例61岁以下的LBL患者在组织学检查后被确定。方案规定大剂量蒽环类抗生素方案，每15天给药一次，诱导4个周期，持续时间≤ 6个月。共有23名患者接受了高剂量治疗巩固，随后进行自体干细胞移植，69名患者接受了标准化疗方案。临床特征显示男性占优势（66%），中位年龄为31岁，骨髓（BM）受累（22%），纵隔受累（66%）和LDH升高（62%）。在治疗结束时，71%的患者达到完全缓解; 4例（4%）患者在诱导期间死亡; 43例患者在中位时间10个月时复发。中位随访时间为34个月，5年总生存率（OS）和无事件生存率（EFS）分别为32%和22%。与生存率显著相关的唯一有利因素是年轻。这些结果是较差的，比在其他侵袭性淋巴瘤用相同的方案治疗，并建议成人LBL患者应与急性淋巴细胞白血病方案治疗。
Since 1987, the GELA has initiated multicenter prospective trials for aggressive non-Hodgkin's lymphomas (NHL). Lymphoblastic lymphomas (LBL) were included in those studies until 1997, and 92 LBL patients under 61 years were identified after histological review. The protocols prescribed high-dose anthracycline regimens, four cycles given every 15 days as induction and lasted for less than or equal to6 months. A total of 23 patients underwent high-dose therapy consolidation followed by autologous stem-cell transplantation and 69 received standard chemotherapy regimens. Clinical characteristics showed a male predominance (66%) with a median age of 31 years, bone marrow (BM) involvement (22%), mediastinal involvement (66%) and elevated LDH (62%). At the end of treatment, it was seen that 71% of the patients achieved complete remission; four (4%) patients died during induction; 43 patients relapsed at a median time of 10 months. With a median follow-up of 34 months, the 5-year overall survival (OS) and event-free survival (EFS) rates were 32 and 22%, respectively. The only favorable factor significantly associated with survival was young age. These results are poorer than those obtained in other aggressive lymphomas treated with the same regimens and suggest that adult LBL patients should be treated with acute lymphoblastic leukemia protocols.